ACB:NSD-Aurora Cannabis Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 1.20

Change

0.00 (0.00)%

Market Cap

USD 0.36B

Volume

0.01B

Avg Analyst Target

USD 3.98 (+231.25%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACB Stock Forecast & Price:
Based on the Aurora Cannabis Inc stock forecasts from 6 analysts, the average analyst target price for Aurora Cannabis Inc is USD 3.98 over the next 12 months. Aurora Cannabis Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Aurora Cannabis Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Aurora Cannabis Inc’s stock price was USD 1.20. Aurora Cannabis Inc’s stock price has changed by -16.08% over the past week, -23.57% over the past month and -79.83% over the last year.

About Aurora Cannabis Inc (ACB:NSD)

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in th ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD PPD Inc

N/A

USD16.61B 47.04 21.58
VTRS Viatris Inc

N/A

USD10.84B 14.19 6.61
NBIX Neurocrine Biosciences Inc

N/A

USD10.10B 812.54 215.33
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
LNTH Lantheus Holdings Inc

N/A

USD4.83B 175.65 46.18
ITCI Intracellular Th

N/A

USD4.18B N/A -12.06
ALKS Alkermes Plc

N/A

USD3.67B N/A -231.07
EVO Evotec SE ADR

N/A

USD3.25B 458.50 69.28

ETFs Containing ACB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -77.82% 26% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.82% 26% F 12% F
Trailing 12 Months  
Capital Gain -79.83% 33% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.83% 33% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 65.32% 95% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.32% 95% A 93% A
Risk Return Profile  
Volatility (Standard Deviation) 264.46% 5% F 4% F
Risk Adjusted Return 24.70% 84% B 62% D-
Market Capitalization 0.36B 67% D+ 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.15 25% F 21% F
Price/Book Ratio 0.73 80% B- 85% B
Price / Cash Flow Ratio -3.28 71% C- 58% F
EV/EBITDA -0.15 36% F 51% F
Management Effectiveness  
Return on Equity -127.26% 23% F 12% F
Return on Invested Capital -14.09% 62% D- 39% F
Return on Assets -7.68% 60% D- 37% F
Debt to Equity Ratio 30.17% 52% F 50% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.75 43% F 49% F
Short Percent 20.42% 5% F 6% F
Beta 2.99 5% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector